Ethicon Endo-Surgery Picks Up Obesity Neurostim Patents From Cyberonics
This article was originally published in The Gray Sheet
Johnson & Johnson subsidiary Ethicon Endo-Surgery expanded its obesity treatment portfolio Dec. 18, gaining exclusive rights to neurostimulation patents from Cyberonics
You may also be interested in...
Inverness raises funds for more acquisitions: Diagnostics firm will gross about $728 million from the sale of 11.8 million shares of its common stock at $61.49 each, expected to close Nov. 20, the firm announces Nov. 15. Proceeds are tabbed for working capital and "potential acquisitions or other investments, if and when suitable opportunities arise," the company says. Inverness Medical Innovations, which has inked more than a dozen acquisition deals so far this year, recently indicated that it plans to keep up the pace, with the goal of growing annual revenues to $3 billion by 2012 (1"The Gray Sheet" Nov. 5, 2007, p. 16). The Waltham, Mass.-based company notes that it also may use a portion of the anticipated proceeds from the stock offering to complete its pending $37 million acquisition of Australian diagnostics firm Panbio, which was announced Oct. 8 (2"The Gray Sheet" Oct. 15, 2007, In Brief). Underwriters for the stock offering include UBS Investment Bank, Jefferies & Company, Merrill Lynch, Leerink Swann, and Stifel, Nicolaus & Company. Inverness stock trades on the Amex exchange under the symbol "IMA.
With Johnson & Johnson expected to launch its Realize adjustable gastric band in the United States by the end of the year, what physicians and analysts consider a highly underpenetrated market will finally have some competition
As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.